Dyne Therapeutics reports FY2024 net loss $317.4M; advances DYNE-101 and DYNE-251 toward accelerated approval

Dyne Therapeutics, Inc.

2024-FY EPS reported -$3.37

FDA granted Fast Track designation for DYNE-101 in DM1; registrational expansion cohort enrollment planned mid-2025.
DYNE-251 in DMD: registrational expansion cohort enrollment targeted Q1 2025; data expected late 2025.
Cash and equivalents $642.3M at Dec 31, 2024; plus $140.6M from ATM in Q1 2025; runway into H2 2026.
Q4 2024 net loss $89.5M ($0.88 per share) vs $66.6M (Q4 2023); R&D expenses $81.8M (Q4 2024).
Potential U.S. accelerated approval submissions for DYNE-101 in H1 2026 and DYNE-251 in early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.